Shattuck Labs, Inc. Operating Lease, Liability, Current
Shattuck Labs, Inc. (STTK) had Operating Lease, Liability, Current of $874.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability, Current $874.00K.
- 2026-03-31: Operating Lease, Liability, Current $852.00K.
- 2025-12-31: Operating Lease, Liability, Current $837.00K.
- 2025-09-30: Operating Lease, Liability, Current $873.00K.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $874.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $852.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $837.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $873.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $956.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $927.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $900.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $873.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $847.00K 10-Q · filed 2024-08-01 |
| 2024-03-31 | $821.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $796.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $771.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $747.00K 10-Q · filed 2023-08-10 |
| 2022-12-31 | $701.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $679.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $657.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $607.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |